A CpG oligodeoxynucleotide potentiates the anti-tumor effect of HSP65-Her2 fusion protein against Her2 positive B16 melanoma in mice.
Although being promising tumor vaccine candidates in animal models, heat shock protein (HSP)-based tumor vaccines have not yet succeeded in the clinical trials, implying the necessity to be formulated with appropriate adjutants to enhance their immunogenicity. In this study, we investigated whether a B-class CpG ODN (BW006), a TLR9 agonist, could facilitate HSP65-Her2, a recombinant protein between mycobacterial HSP65 and Her2-derived peptide, to induce vigorous anti-tumor activity against Her2 positive tumors in mice both prophylactically and therapeutically. It was found that BW006 could enhance prophylactic and therapeutic effect of HSP65-Her2 with improved survival of the mice bearing Her2(+) B16 melanoma and HSP65-Her2 specific Th1 response.
Department of Immunology, Norman Bethune College of Medicine, Jilin University, Changchun 130021, China.
Youyou
Y
Yan
Zhao
Z
Cao
Ming
M
Yang
He
H
Li
Hongfei
H
Wei
Yao
Y
Fu
Dandan
D
Song
Liying
L
Wang
Yongli
Y
Yu
D000818:Animals; D001426:Bacterial Proteins / Q000494:pharmacology*; D019496:Cancer Vaccines / Q000494:pharmacology*; D018834:Chaperonin 60 / Q000494:pharmacology*; D005260:Female; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D018417:Th1 Cells / Q000187:drug effects; D051217:Toll-Like Receptor 9 / Q000037:antagonists & inhibitors
D001426:Bacterial Proteins; D019496:Cancer Vaccines; D018834:Chaperonin 60; D009838:Oligodeoxyribonucleotides; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; D051217:Toll-Like Receptor 9; C408982:CPG-oligonucleotide; C495370:Tlr9 protein, mouse; C074119:heat-shock protein 65, Mycobacterium